ESPR - エスペリオン・セラピュ―ティクス （Esperion Therapeutics Inc.）

Gainers Virgin Orbit Holdings, Inc. (NASDAQ: VORB ) jumped 25.6% to $0.2512 in pre-market trading. Virgin Orbit Communications shares jumped 34% on Wednesday after a Telegraph report suggested the company is working with lawyers to agree on an emergency cash injection of around $31 million. LumiraDx Limited (NASDAQ: LMDX ) gained 20% to $0.66 in pre-market trading after gaining around 8% on Wednesday. Liquid Media Group Ltd. (NASDAQ: YVR ) gained 18.1% to $0.17 in pre-market trading. SeaChange International, Inc. (NASDAQ: SEAC ) gained 17.1% to $0.48 in pre-market trading after the company reported a rise in Q4 earnings. Esperion Therapeutics, Inc. (NASDAQ: ESPR ) shares climbed 15.1% to $1.45 in pre-market trading after declining 8% on Wednesday. Esperion recently announced a $56.7 million registered direct offering with institutional investors. AMC Entertainment Holdings, Inc. (NYSE: AMC ) gained 12.8% to $4.57 in pre-market trading. AMC Entertainment 13G Filing showed Millennium Management reported a 5.3% passive stake in the company as of March 30, 2023.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock''s strength on days when prices go up to its strength on days when prices go down. When compared to a stock''s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. Esperion Therapeutics, Inc. (NASDAQ: ESPR ) Esperion announced a $56.7 million registered direct offering with institutional investors. The company’s stock has a 52-week low of $1.26 . RSI Value: 22.41 ESPR Price Action: Shares of Esperion Therapeutics jumped 4.8% to close at $1.76 on Tuesday. SELLAS Life Sciences Group, Inc. (NASDAQ: SLS ) SELLAS Life Sciences posted a FY22 loss of $2.13 … Full story available on Benzinga.com

Investors are on the hunt for undervalued, underfollowed and emerging stocks when it comes to spotting opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of March 16, 2023. Jounce Therapeutics (NASDAQ: JNCE ): Shares of Jounce are up over 70% in the last five days. The move comes after the company shared data from its Phase 2 trial of JTX-8064 and pimivalimab among patients with ovarian cancer. The company is looking for a partner on JTX-8064. The strong results could help the company secure a partner and be what investors are betting on.

Lipella Pharmaceuticals (LIPO) +48%. ThermoGenesis Holdings (THMO) +34%. Esperion Therapeutics (ESPR) -66%. Paratek Pharmaceuticals (PRTK) -18%.

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 31,713.71 while the NASDAQ fell 0.18% to 11,412.93. The S&P 500, also fell, dropping, 0.33% to 3,879.20. Check This Out: Top 5 Tech Stocks Which You''ll Regret Missing This Quarter Leading and Lagging Sectors Communication services shares rose by 0.1% on Thursday. Meanwhile, top gainers in the sector included iHuman Inc. (NYSE: IH ), up 3%, and CarGurus, Inc. (NASDAQ: CARG ), up 1%. In trading on Thursday, energy shares tumbled by 1.4%. Top Headline US initial jobless claims dropped by 20,000 from the prior week to 192,000 in the week ending March 11, compared to market expectations of 205,000. Equities Trading UP PureCycle Technologies, Inc. (NASDAQ: PCT ) shares shot up 33% to $6.36 after the company provided a Q4 2022 update. Shares of UiPath Inc. (NYSE: PATH ) got a boost, shooting 19% to $17.45 after the company reported better-than-expected Q4 results and issued strong revenue guidance.

The share price of Esperion Therapeutics Inc. (NASDAQ:ESPR) fell to $6.07 per share on Friday from $6.36. While Esperion Therapeutics Inc. has underperformed by -4.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ESPR rose by 12.83%, with highs and lows ranging from $8.87 to $3.28, […]

Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 0.23 and has seen 2.43 million shares traded in the last trading session. The company, currently valued at $501.03M, closed the last trade at $5.60 per share which meant it gained $0.23 on the day or 4.28% during that session. The ESPR stock price is -58.39% … Esperion Therapeutics Inc. (ESPR) Has Strong Growth Prospects Through 2022 Read More »

Esperion Therapeutics Inc. (ESPR)’s stock has witnessed a price declined of -0.29% from the previous close with its current price standing at $5.07. Its current price is -42.78% under its 52-week high of $8.87 and 54.73% more than its 52-week low of $3.28. Based on the past 30-day period, the stock price is -42.90% below […]

During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares were 7.06 million, with the beta value of the company hitting 0.21. At the end of the trading day, the stock’s price was $5.09, reflecting an intraday loss of -17.64% or -$1.09. The 52-week high for the ESPR share is $8.87, that puts it down … Following Its 52-Week Low, Esperion Therapeutics Inc. (NASDAQ: ESPR)’S Share Price Rose 35.56% And Its YTD Numbers Rise 1.80% Read More »

Prometheus Biosciences (RXDX) and Esperion Therapeutics (ESPR) are both making waves following drug updates

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Flickering stocks: Esperion Therapeutics, Inc. (NASDAQ:ESPR -10.01%), TechnipFMC plc (NYSE:FTI 1.88%) appeared first on Stocks Equity .

Wall Street brokerages forecast that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will report ($2.86) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Esperion Therapeutics earnings. The lowest EPS estimate is ($3.05) and the highest is ($2.63). Esperion Therapeutics reported earnings of ($3.07) per share in the same quarter []

Wall Street analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report sales of $12.31 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Esperion Therapeutics earnings, with the highest sales estimate coming in at $13.00 million and the lowest estimate coming in at $11.23 million. Esperion Therapeutics posted sales []

SG Americas Securities LLC lessened its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 14.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,844 shares of the biopharmaceutical companys stock after selling 2,422 shares during the period. SG Americas []

Credit Suisse Group lowered shares of Esperion Therapeutics (NASDAQ:ESPR) from an outperform rating to a neutral rating in a report released on Monday, PriceTargets.com reports. The firm currently has $11.00 price target on the biopharmaceutical companys stock, down from their previous price target of $28.00. Several other equities analysts also recently issued reports on the []